Striatum

Introduction

Striatum is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

The striatum is the largest nucleus of the basal-ganglia and serves as the primary input structure for this subcortical motor circuit. Composed of two main divisions—the caudate nucleus and the putamen—separated by the internal capsule, the striatum integrates excitatory glutamatergic inputs from the cerebral cortex and thalamus with modulatory dopaminergic signals from the substantia-nigra pars compacta . The striatum plays essential roles in motor control, action selection, reward processing, and habit formation. It is among the most severely affected brain regions in huntington-pathway and is critically involved in parkinsons through loss of dopaminergic input . ^{1Sidell KR, Amamath V, Montine TJ, Dopamine thioethers in neurodegeneration (2001)2001 · DOI 10.2174/1568026013394705Open reference}

Overview

The striatum (from Latin striatus, meaning “grooved” or “striped”) derives its name from the striped appearance caused by alternating bundles of gray and white matter. It is the primary gateway for cortical information entering the basal ganglia and is essential for translating cognitive and motivational signals into appropriate motor actions . ^{2Gil JM, Rego AC, Mechanisms of neurodegeneration in Huntington's Disease (2008)2008 · DOI 10.1111/j.1460-9568.2008.06310.xOpen reference}

The striatum is divided into functional territories: ^{3Gibb WR, Functional neuropathology in Parkinson's Disease (1997)1997 · DOI 10.1159/000113472Open reference}

• Dorsal striatum (caudate nucleus and putamen): Primarily involved in motor control and habit learning

• Ventral striatum (nucleus accumbens and olfactory tubercle): Involved in reward, motivation, and reinforcement learning

Approximately 90–95% of striatal neurons are medium spiny neurons (MSNs), also called spiny projection neurons (SPNs), which are GABAergic inhibitory neurons that constitute the sole output of the striatum . The selective vulnerability of these neurons underlies the devastating motor and cognitive symptoms of several neurodegenerative diseases. ^{4Whetsell WO, The mammalian striatum and neurotoxic injury (2002)2002 · DOI 10.1111/j.1750-3639.2002.tb00466.xOpen reference}

Anatomy and Organization

Gross Anatomy

The striatum is a large, curved structure situated deep within the cerebral hemispheres: ^{5Motor Progression and Nigrostriatal Neurodegeneration in Parkinson Disease (2022)2022 · DOI 10.1002/ana.26373Open reference}

• Caudate nucleus: A C-shaped structure with a large head (adjacent to the lateral ventricle), a body, and a thin tail that curves into the temporal lobe. The caudate is involved in cognitive functions, goal-directed behavior, and eye movements .

• Putamen: The largest component of the basal ganglia, located lateral to the globus pallidus and medial to the external capsule. The putamen is primarily involved in motor control and motor learning.

• Nucleus accumbens: Located at the junction of the caudate head and putamen in the ventral striatum. It plays a central role in the reward circuit and is critical for motivation and addiction.

Compartmental Organization: Striosomes and Matrix

The striatum has a complex compartmental organization consisting of two interdigitating compartments: ^{6Ahlers-Dannen KE, Spicer MM, Fisher RA, RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease (2020)2020 · DOI 10.1124/mol.119.118836Open reference}

• Striosomes (patches): Comprise approximately 10–15% of striatal volume. These compartments receive input from limbic cortical areas and project to the substantia-nigra pars compacta, providing feedback to dopaminergic neurons. Striosomes are enriched in mu-opioid receptors and are preferentially vulnerable in huntington-pathway.

• Matrix: The larger compartment, comprising 85–90% of striatal volume. Matrix MSNs receive input from sensorimotor and associative cortical areas and project to the globus pallidus and substantia nigra pars reticulata. The matrix is enriched in acetylcholinesterase and calbindin.

Recent research from MIT (2023) demonstrated that these compartments are differentially affected in huntington-pathway, with striosome degeneration potentially accounting for mood and motivational disturbances, while matrix degeneration produces motor impairments . ^{7Kernie SG, Parent JM, Forebrain neurogenesis after focal Ischemic and traumatic brain injury (2010)2010 · DOI 10.1016/j.nbd.2009.11.002Open reference}

Cellular Composition

Medium Spiny neurons (MSNs): Constitute approximately 90–95% of all striatal neurons. These GABAergic projection neurons are characterized by their medium-sized soma (12–20 μm) and densely spiny dendrites. MSNs exist in two major subtypes :

• D1-MSNs (direct pathway): Express dopamine D1 receptors, substance P, and dynorphin. They project directly to the globus pallidus internus (GPi) and substantia nigra pars reticulata (SNr), facilitating movement.

• D2-MSNs (indirect pathway): Express dopamine D2 receptors and enkephalin. They project to the globus pallidus externus (GPe), inhibiting movement.

Interneurons: Although comprising only 5–10% of striatal neurons, interneurons exert powerful control over MSN activity:

• Cholinergic interneurons (ChATs): Large, tonically active neurons that release acetylcholine. They play a critical role in reward learning and behavioral flexibility.

• Parvalbumin-positive (PV+) fast-spiking interneurons: Provide strong feedforward inhibition to MSNs.

• Somatostatin/neuropeptide Y/NOS interneurons: Involved in nitric oxide signaling and neuromodulation.

• Calretinin-positive interneurons: Less well characterized, involved in local circuit regulation.

Neural Circuits

Direct Pathway

The direct pathway promotes movement and facilitates desired motor programs :

1. cortex → glutamate → D1-MSNs in striatum (excitatory)

2. D1-MSNs → gaba → GPi/SNr (inhibitory)

3. GPi/SNr → GABA → thalamus (disinhibition, net excitation)

4. Thalamus → Glutamate → Motor cortex (excitatory)

dopamine from the substantia-nigra pars compacta activates D1 receptors on direct pathway MSNs, enhancing their activity and promoting movement.

Indirect Pathway

The indirect pathway suppresses competing or unwanted movements:

1. cortex → Glutamate → D2-MSNs in striatum (excitatory)

2. D2-MSNs → GABA → GPe (inhibitory)

3. GPe → GABA → Subthalamic nucleus (disinhibition)

4. Subthalamic nucleus → Glutamate → GPi/SNr (excitatory)

5. GPi/SNr → GABA → Thalamus (inhibition)

Dopamine inhibits D2-MSNs via D2 receptors, reducing indirect pathway activity and thereby reducing movement suppression. Loss of dopaminergic input in Parkinson’s disease leads to overactivation of the indirect pathway, producing akinesia and rigidity.

Hyperdirect Pathway

The hyperdirect pathway provides the fastest route for cortical control of basal ganglia output:

• cortex → Glutamate → Subthalamic nucleus → Glutamate → GPi/SNr

• This pathway bypasses the striatum and enables rapid suppression of all motor programs, critical for response inhibition and action cancellation.

Role in Neurodegenerative Diseases

Huntington’s Disease

huntington-pathway is characterized by profound and selective degeneration of striatal MSNs, making the striatum the most affected brain region :

• Selective vulnerability: D2-MSNs of the indirect pathway are preferentially lost in early disease, producing chorea (involuntary movements) through disinhibition of the direct pathway

• Disease progression: As D1-MSNs and remaining D2-MSNs degenerate, chorea gives way to rigidity, dystonia, and akinesia in later stages

• Striosomal pathology: Research has shown that striosome neurons are affected early and distinctly, contributing to mood disorders and cognitive decline

• huntingtin protein aggregation: Mutant huntingtin with expanded polyglutamine repeats forms intranuclear inclusions in MSNs

• Dopamine dysregulation: During the early hyperkinetic stage, dopamine levels are increased while dopamine receptor expression is reduced; in the late akinetic stage, dopamine levels decrease significantly

Vonsattel grading classifies striatal pathology in HD from Grade 0 (no visible atrophy, 30–40% neuronal loss) to Grade 4 (severe atrophy with >95% neuronal loss), with a dorsomedial-to-ventrolateral gradient of degeneration .

Parkinson’s Disease

In parkinsons, the striatum itself does not primarily degenerate, but it loses its critical dopaminergic input due to substantia-nigra pars compacta neuronal death :

• Dopamine depletion: Striatal dopamine levels can decrease by 60–80% before motor symptoms appear, highlighting the striatum’s compensatory capacity

• Asymmetric involvement: The putamen (posterior and dorsal) is affected before the caudate, consistent with the somatotopic organization of motor cortical inputs

• Synaptic dysfunction: Recent 2025 research demonstrates that axonal synaptic dysfunction precedes overt neuronal loss, with early changes in striatal dopamine release occurring without concomitant reduction in dopamine content

• D2 receptor upregulation: A 2025 PET imaging study revealed compensatory upregulation of dopamine D2 receptors in the dorsal striatum in the lrrk2-R1441C model of early PD

• alpha-synuclein pathology: Lewy neurites are found in striatal terminals of dopaminergic axons

Multiple System Atrophy (MSA)

In MSA-P (parkinsonian subtype), the striatonigral system degenerates with prominent putaminal pathology:

• Neuronal loss and gliosis in the posterolateral putamen

• Glial cytoplasmic inclusions (GCIs) containing alpha-synuclein in striatal oligodendrocytes

• Putaminal atrophy and iron deposition visible on MRI as a hyperintense lateral putaminal rim

Corticobasal Degeneration (CBD)

corticobasal-degeneration involves asymmetric cortical and basal ganglia tau] pathology:

• Astrocytic plaques and tau]-positive neuronal inclusions in the striatum

• Striatal atrophy contributing to parkinsonism and dystonia

• Caudate and putaminal involvement with 4-repeat tauopathy

Other Conditions

• wilson-disease: Copper deposition causes striatal necrosis, particularly in the putamen

• neurodegeneration-brain-iron-accumulation: Iron accumulates in the globus pallidus and striatum, with the “eye of the tiger” sign on MRI in pkan

• Chorea: Various forms of chorea (Sydenham’s, autoimmune) involve striatal dysfunction

• Addiction and reward disorders: Ventral striatal dysfunction in substance use disorders

Neurotransmitter Dynamics

The striatum is a major site of dopamine neurotransmission, and its neurotransmitter dynamics are central to understanding basal ganglia function and disease :

Neurotransmitter	Source	Receptor(s)	Function
dopamine	substantia-nigra pars compacta	D1, D2, D3, D4, D5	Modulates direct/indirect pathway balance
glutamate	cortex, thalamus	AMPA, nmda-receptor receptor], mGluR	Excitatory drive to MSNs
gaba	MSN collaterals, interneurons	GABA-A, GABA-B	Local inhibition, MSN output
acetylcholine	Cholinergic interneurons	nAChR, mAChR	Reward signaling, plasticity
serotonin	Raphe nuclei	5-HT1B, 5-HT2C, 5-HT6	Modulates dopamine release
Endocannabinoids	MSNs (retrograde)	CB1	Retrograde synaptic modulation

Synaptic Plasticity

The striatum exhibits robust forms of synaptic plasticity that underlie motor learning and habit formation:

• Long-term potentiation (LTP): Strengthening of corticostriatal synapses, dependent on D1 receptor activation and NMDA receptor signaling

• Long-term depression (LTD): Weakening of corticostriatal synapses, dependent on D2 receptor activation and endocannabinoid signaling

• Dopamine-dependent plasticity: The direction of plasticity (long-term-potentiation vs. LTD) is critically modulated by dopamine, explaining why dopamine depletion in Parkinson’s disease disrupts motor learning

Diagnostic Imaging

Several imaging modalities assess striatal structure and function:

• DaTSCAN (DAT-SPECT): Measures dopamine transporter density in the striatum; reduced uptake in the posterior putamen is an early marker of Parkinson’s disease

• 18F-DOPA PET: Assesses dopamine synthesis capacity in the striatum

• MRI volumetry: Caudate and putaminal atrophy measured on structural MRI; the caudate/ventricle ratio is a marker of huntington-pathway progression

• Quantitative susceptibility mapping (QSM): Detects iron accumulation in the putamen, relevant to MSA and NBIA

• fMRI: Reveals altered striatal activation patterns in motor tasks and reward processing

Therapeutic Approaches

Dopamine Replacement

• levodopa: The gold standard for Parkinson’s disease, levodopa is converted to dopamine in remaining striatal dopaminergic terminals

• dopamine-agonists: Directly stimulate striatal dopamine receptors (pramipexole, ropinirole)

• MAO-B inhibitors: Prevent striatal dopamine degradation (mao-b-inhibitors

• COMT inhibitors: Extend levodopa’s duration of action (entacapone, opicapone)

Deep Brain Stimulation

deep-brain-stimulation targets structures closely connected to the striatum:

• Subthalamic nucleus (STN) DBS: Most common target for parkinsons, modulates indirect pathway activity

• GPi DBS: Used for dystonia and Parkinson’s Disease, directly modulates basal ganglia output

Emerging Therapies

• gene-therapy: AAV-mediated delivery of glutamic acid decarboxylase (GAD) to the subthalamic nucleus; AADC gene therapy directly to the putamen

• Cell replacement: stem-cell-therapy to replace lost dopaminergic innervation of the striatum

• huntingtin-lowering therapies: antisense-oligonucleotide-therapy and siRNA targeting mutant huntingtin expression in the striatum

• [Medium Spiny [Neurons (MSNs)/cell-types/medium-spiny-neurons

Background

The study of Striatum has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• PubMed - Biomedical literature

• Alzheimer’s Disease Neuroimaging Initiative - Research data

• Allen Brain Atlas - Brain gene expression data

Brain Atlas Resources

This section links to atlas resources relevant to this brain region.

• Allen Human Brain Atlas: Striatum expression search

• Allen Mouse Brain Atlas: Striatum search

• Allen Cell Type Atlas: Transcriptomic cell type reference

• BrainSpan Developmental Transcriptome: Striatum developmental expression